Antibiotic activity in vitro against methicillin-resistant Staphylococcus epidermidis and therapy of an experimental infection.
Staphylococcus epidermidis is a major pathogen in early prosthetic valve endocarditis and cerebrospinal fluid shunt infections. Approximately 10 to 15% of hospital isolates are methicillin resistant. Ten clinically significant isolates of the latter were collected for antibiotic studies in vitro and in an experimental infection in animals. Time-kill studies of five strains showed gentamicin to be the single most effective antibiotic; however, dwarf colony variants emerged as survivors with two of these strains when challenged with gentamicin alone. The addition of a second antibiotic to gentamicin did not significantly improve the bactericidal rate but prevented the emergence of variant strains. A blood culture isolate of methicillin-resistant S. epidermidis combined with 5% hog gastric mucin was used to establish an experimental intraperitoneal infection in mice. Neither methicillin nor nafcillin treatment reduced mortality below that of untreated animals. Cephalothin treatment delayed early mortality but did not diminish overall mortality. Gentamicin was the most effective single antibiotic, and gentamicin in combination with vancomycin was the most effective regimen overall. The combination of rifampin plus vancomycin was as effective as gentamicin alone. The combinations of cephalothin or nafcillin with gentamicin and cephalothin with vancomycin demonstrated antagonism. The antagonism was not due to multiple injections or drug-drug inactivation.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D008712:Methicillin / Q000494:pharmacology; D051379:Mice; D008826:Microbial Sensitivity Tests; D010403:Penicillin Resistance; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013210:Staphylococcus / Q000187:drug effects*; D013997:Time Factors
D000900:Anti-Bacterial Agents; D008712:Methicillin
Bacteriol Rev. 1948 Jun;12(2):149-72
16350119
Proc Soc Exp Biol Med. 1963 Aug-Sep;113:1023-31
14073098
J Bacteriol. 1951 Nov;62(5):663-8
14897844
Medicine (Baltimore). 1977 Jul;56(4):287-313
875718
Antimicrob Agents Chemother. 1978 Sep;14(3):353-9
708013
J Infect Dis. 1978 Mar;137(3):245-50
632623
Antimicrob Agents Chemother. 1972 May;1(5):441-6
4494488
JAMA. 1971 Feb 22;215(8):1297-300
5107559
Antimicrob Agents Chemother (Bethesda). 1968;8:302-6
5195738
Contrib Microbiol Immunol. 1973;1:650-8
4805328
Am J Med. 1971 Jul;51(1):83-96
5570321
Am J Clin Pathol. 1966 Apr;45(4):493-6
5325707
Lancet. 1967 Jan 7;1(7480):17-9
4163737
Ann N Y Acad Sci. 1974 Jul 31;236(0):413-34
4608264
Antimicrob Agents Chemother. 1976 Mar;9(3):414-7
176933
J Infect Dis. 1972 Dec;126(6):674-8
4489479
J Lab Clin Med. 1974 Feb;83(2):241-8
4810952
Pediatrics. 1974 Jan;53(1):55-62
4809195
Circulation. 1973 Jun;47(6):1319-26
4709547
J Lab Clin Med. 1971 Sep;78(3):457-63
4999161
N Engl J Med. 1966 Jan 27;274(4):199-206 contd
5323087
Ann N Y Acad Sci. 1970 Oct 30;174(2):533-44
5278134
Ann N Y Acad Sci. 1971 Jun 11;182:258-66
5285290
Antimicrob Agents Chemother. 1976 Jun;9(6):962-9
938025
Antimicrob Agents Chemother. 1975 Sep;8(3):344-9
1167043
J Infect Dis. 1975 May;131(5):543-52
1127260
J Infect Dis. 1975 Mar;131(3):245-51
1127254
J Clin Pathol. 1968 Nov;21(6):722-8
5191722
Ann N Y Acad Sci. 1965 Jul 23;128(1):428-42
5216765
N Engl J Med. 1967 Sep 28;277(13):678-80
5182623
Surg Gynecol Obstet. 1970 Jan;130(1):94-8
5410639